EXH.06 / CONTACT
editorial correspondence
We accept editorial correspondence — corrections, source suggestions, and pointers to new published research. We do not respond to product, prescription, or treatment inquiries.
What we read
The studio reads editorial mail. We are interested in three kinds of correspondence in particular: factual corrections to anything on the site, pointers to newly published peer-reviewed research on AOD-9604 that we have not yet incorporated, and reasoned source suggestions for adjacent topics we have not yet covered. Briefer is better. A short note with a DOI is more useful to us than a long argument without one.
What we do not respond to
We are an editorial publication, not a clinic. We do not respond to inquiries about obtaining AOD-9604, about whether AOD-9604 is right for a particular person or condition, about dosing protocols, about vendors, about compounding pharmacies, about telehealth providers, or about anything else that would constitute medical or product advice. We also do not respond to commercial outreach from research-peptide vendors, supplement companies, or peptide-clinic operators; we do not partner with vendors and we do not run sponsored content. None of the contact channels listed below should be construed as a clinical, prescribing, or counselling relationship.
Contact form
Use the form below to send editorial correspondence. We aim to acknowledge useful notes within a reasonable timeframe but do not commit to individual responses. If you are pointing us to a paper, please include the DOI or PubMed URL in the message body — we will not chase down ambiguous citations.
This site is an editorial research digest. Submissions are read as editorial correspondence only. Nothing sent through this form establishes a clinical, prescribing, or counselling relationship. Do not include personal medical information.